Publications by authors named "Robert T Foster"

Claim this Profile
C
Cyclophilin Inhibitor Rencofilstat Combined with Proteasome Inhibitor Ixazomib Increases Proteotoxic Cell Death in Advanced Prostate Cancer Cells with Minimal Effects on Non-Cancer Cells.
Carlos Perez-Stable, Alicia de Las Pozas, Medhi Wangpaichitr, Robert T Foster, Daren R Ure

Biomedicines· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Chemotherapy Combination to Enhance Proteotoxic Cell Death in Hepatocellular Carcinoma Experimental Models Without Killing Non-Cancer Cells.
Carlos Perez-Stable, Alicia de Las Pozas, Teresita Reiner, Jose Gomez, Manojavan Nagarajan, Robert T Foster

Int J Mol Sci· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH.
Winston T Stauffer, Michael Bobardt, Daren R Ure, Robert T Foster, Philippe Gallay

PLoS One· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mice lacking cyclophilin B, but not cyclophilin A, are protected from the development of NASH in a diet and chemical-induced model.
Winston T Stauffer, Asha Z Goodman, Michael Bobardt, Daren R Ure, Robert T Foster

PLoS One· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a High-Fat Meal on Single-Dose Rencofilstat (CRV431) Oral Bioavailability in Healthy Human Subjects.
Ellen Remenchik, Patrick R Mayo, Todd M Hobbs, Jill A Greytok, Erin P Foster, Robert T Foster

Clin Pharmacol Drug Dev· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single-blind, placebo-controlled study in F2/F3 NASH.
Stephen A Harrison, Patrick R Mayo, Todd M Hobbs, Carlos Canizares, Erin P Foster, Robert T Foster

Hepatol Commun· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH).
Daren R Ure, Daniel J Trepanier, Patrick R Mayo, Robert T Foster

Expert Opin Investig Drugs· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.
Joseph Kuo, Michael Bobardt, Udayan Chatterji, Patrick R Mayo, Daniel J Trepanier, Robert T Foster

J Pharmacol Exp Ther· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development, Characterization, and Pharmacokinetic Evaluation of a CRV431 Loaded Self-Microemulsifying Drug Delivery System.
Daniel J Trepanier, Daren R Ure, Robert Thomas Foster

J Pharm Pharm Sci· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro Phase I Metabolism of CRV431, a Novel Oral Drug Candidate for Chronic Hepatitis B.
Daniel J Trepanier, Daren R Ure, Robert T Foster

Pharmaceutics· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.
Spencer Y Ling, Robert B Huizinga, Patrick R Mayo, Richard Larouche, Derrick G Freitag, Robert T Foster

Br J Clin Pharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Voclosporin food effect and single oral ascending dose pharmacokinetic and pharmacodynamic studies in healthy human subjects.
Patrick R Mayo, Robert B Huizinga, Spencer Y Ling, Derrick G Freitag, Launa J Aspeslet, Robert T Foster

J Clin Pharmacol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
ISA247: quality of life results from a phase II, randomized, placebo-controlled study.
Aditya K Gupta, Richard G Langley, Charles Lynde, Kirk Barber, Wayne Gulliver, Robert T Foster

J Cutan Med Surg· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis.
Robert Bissonnette, Kim Papp, Yves Poulin, Gilles Lauzon, Launa Aspeslet, Robert T Foster

J Am Acad Dermatol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of cimetidine co-administration on the pharmacokinetics of acebutolol enantiomers and its metabolite diacetolol in a rat model: the effect of gastric pH on double-peak phenomena.
S Abolfazl Mostafavi, Robert T Foster

Int J Pharm· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amelioration of accelerated collagen induced arthritis by a novel calcineurin inhibitor, ISA(TX)247.
Walter P Maksymowych, Gian S Jhangri, Launa Aspeslet, Mark D Abel, Daniel J Trepanier, Robert T Foster

J Rheumatol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis